Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD

Pharmacology, Toxicology and Pharmaceutical Science

1. Cytokine 100%
2. Alzheimer Disease 100%
3. Mild Cognitive Impairment 100%
4. Nervous System Inflammation 100%
5. Diseases 77%
6. Drug 66%
7. Injury 44%
8. Pharmacodynamics 33%
9. Human Study 22%
10. Adverse Event 22%
11. Central Nervous System Disease 11%
12. Animal 11%
13. Traumatic Brain Injury 11%
14. Guanosine Phosphate 11%
15. Safety Pharmacology 11%
16. Mouse Model 11%
17. Drug Discovery 11%
18. Mouse 11%
19. Clinical Research 11%
20. Pathophysiology 11%
21. Target Activity 11%
22. Toxicology 11%
23. Disease Exacerbation 11%
24. Neurologic Disease 11%
25. Tumor Growth 11%
26. Pharmaceutical Chemistry 11%
27. Water 11%
28. Metastasis 11%
29. Cognitive Defect 11%
30. Dementia 11%
31. Clinical Study 11%
32. Chemical Stability 11%